Advertisement
Screener

IN8BIO, INC. (INAB) Construction in Progress Expenditures Incurred but Not yet Paid

1.1 / 5 stars · 4/19 Roast Me

IN8BIO, INC. Construction in Progress Expenditures Incurred but Not yet Paid

IN8BIO, INC. (INAB) reported Construction in Progress Expenditures Incurred but Not yet Paid of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid · last filed 2024-11-12

  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $0.00.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for the quarter ending 2023-12-31 was -$24.00K.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for the quarter ending 2023-09-30 was -$24.00K, a 112.50% decline year-over-year.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for the quarter ending 2022-12-31 was -$663.00K, a 1135.94% decline year-over-year.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for fiscal 2022 was $13.00K, a 86.17% decline from fiscal 2021.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for fiscal 2021 was $94.00K.
  • IN8BIO, INC. construction in progress expenditures incurred but not yet paid for fiscal 2020 was $0.00.
Period endConstruction in Progress Expenditures Incurred but Not yet Paid 3 monthConstruction in Progress Expenditures Incurred but Not yet Paid 6 monthConstruction in Progress Expenditures Incurred but Not yet Paid 9 monthConstruction in Progress Expenditures Incurred but Not yet Paid 12 month
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$0.00
10-Q · filed 2024-11-12
2024-06-30$0.00
10-Q · filed 2024-08-08
2023-12-31-$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$48.00K
derived: sum of 2 quarters · filed 2024-11-12
$0.00
10-K · filed 2024-03-14
2023-09-30-$24.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$24.00K
10-Q · filed 2024-11-12
2023-06-30$48.00K
10-Q · filed 2024-08-08
2022-12-31-$663.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$471.00K
derived: sum of 2 quarters · filed 2024-03-14
$13.00K
10-K · filed 2024-03-14
2022-09-30$192.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$676.00K
10-Q · filed 2023-11-09
2022-06-30$484.00K
10-Q · filed 2023-08-10
2021-12-31$64.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
$94.00K
10-K · filed 2023-03-30
2021-09-30$30.00K
10-Q · filed 2022-11-10
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$0.00
10-K · filed 2022-03-17
2020-09-30$0.00
10-Q · filed 2021-11-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
Pluri Inc. (PLUR)$0.014B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Passage BIO, Inc. (PASG)United States$0.015B-0.43
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B